Entrada Therapeutics promotes COO Nathan Dowden to President, effective Jan 1, 2024

Entrada Therapeutics, Inc.

Nathan J. Dowden promoted to President, retains COO role; Dipal Doshi continues as CEO.
Salary increased to $480,000/year; target bonus raised to 45%.
Granted 60,000 RSUs vesting 50% on 2nd anniversary and 50% on 3rd anniversary.
Dowden has served as COO since Nov 2019 and has 30 years healthcare sector experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Nathan J. Dowden

President and Chief Operating Officer

TRDA · Entrada Therapeutics, Inc.

Effective: 2024-01-01
Filed: January 3, 2024, 6:59 PM ET

appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nathan J. Dowden was appointed as President and Chief Operating Officer at Entrada Therapeutics, Inc..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024

View on SEC.gov

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-000571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.